Bristol Myers Squibb gets European Commission nod for CAR T Cell therapy Breyanzi for relapsed or refractory large B-cell lymphoma after one prior therapy Ruchika Sharma5 May 2023 2:30 PM ISTBreyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.
Bristol Myers Squibb gets positive EMA Committee opinion for Breyanzi for Relapsed or Refractory Large B-cell Lymphoma after one prior therapy Ruchika Sharma2 April 2023 10:00 AM ISTBreyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.
Medical Bulletin 1/April/2023 Isra Zaman1 April 2023 3:40 PM ISTHere are the top medical news for the day:CAR T cells improve patient quality of life: StudyChimeric antigen receptor T-cell (CAR-T) therapies are...
CAR T cells improve patient quality of life: Study Isra Zaman1 April 2023 9:15 AM ISTChimeric antigen receptor T-cell (CAR-T) therapies are developed by harvesting a patient's own T cells (the immune system's primary cancer-killing...
Medical Bulletin 7/February/2023 Isra Zaman7 Feb 2023 3:45 PM ISTHere are the top medical news for the day:Large study suggests no adverse effect of fertility treatment on cardiovascular health of offspringA large...
Study finds hope for ovarian cancer patients in new immunotherapy Isra Zaman7 Feb 2023 9:30 AM ISTCAR T-cell therapy, a certain kind of cancer treatment in which the immune system's T cells are programmed to attack tumour cells, is effective in...
CAR T-cell therapy holds promise for treatment of ovarian cancer Dr. Kamal Kant Kohli7 Feb 2023 2:15 AM ISTCAR T-cell therapy is a certain kind of cancer treatment in which the immune system's T cells are programmed to attack tumour cells. Researchers at...
Gilead Sciences' Kite gets European Commission nod for CAR T-cell therapy Tecartus Ruchika Sharma8 Sept 2022 4:00 PM ISTSanta Monica, Calif.: Kite, a Gilead Company has announced that the European Commission (EC) has approved its CAR T-cell therapy Tecartus...
Bristol Myers Squibb bags USFDA nod for CAR T Cell Therapy Breyanzi Ruchika Sharma26 Jun 2022 4:00 PM ISTBreyanzi, a differentiated CAR T cell therapy, is made from a patient's own T cells, which are collected and genetically reengineered to become CAR T...
Kite gets USFDA nod for new CAR T-cell therapy site in Maryland Ruchika Sharma20 April 2022 1:12 PM ISTSanta Monica: Kite, a Gilead Company has announced the U.S. Food and Drug Administration (USFDA) has approved commercial production at the company's...
Bayer strikes deal with Atara Biotherapeutics to jointly work on CAR-T cell anti-tumour treatments Ruchika Sharma9 Dec 2020 10:15 AM ISTFrankfurt: Bayer AG has struck a deal with Atara Biotherapeutics to jointly work on Atara's CAR-T cell anti-tumour treatments, as the German group...
USFDA extends action date for Bristol Myers Squibb Lisocabtagene Maraleucel (liso-cel) Ruchika Sharma10 May 2020 12:15 PM ISTLiso-cel is an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target CD19
